CD274 and neoplasm: The Au@Pt-LCDP-treated (MMP-responsive switch absent) group showed uncontrolled tumor growth of both the primary and distant tumors after 2 weeks of PTT treatment, attributed to the unsuccessful release of the PD-L1 antagonist (DPPA-1), justifying the efficacy of combinational PD-L1 peptide-based immunotherapy and PTT (Yang et al., 2019b).